Research & Innovation
Women in Science
Education and career development
CNIO and Society
About the CNIO
What is it we do
Thanks to our friends donations
Other contributions: CNIO Arte
CNIO Friends Newsletter
La Caixa-CNIO Frontiers Meetings
Women in Science Office Seminar
Activities & Events
Facts & Figures
Contacts & Suggestions
Links of Interest
Career Development Programmes
How to Find Us
CNIO Open doors
CNIO & The City
CNIO Friends welcomes Víctor Frankenstein
CNIO Friends Newsletter
Outreach to Society
EMBO Molecular Medicine.
CNIO researchers find effective drug combinations for glioblastoma in mice
Usually, scientists study the molecular biology of cancer to find new treatments, but sometimes, it...
Journal of Experimental Medicine.
CNIO researchers assess melanoma progression with a new liquid biopsy technique
When the surgeon surgically removes a melanoma, some patients are said to be ‘cancer-free’ and...
The American Journal of Human Genetics.
CNIO researchers identify a new gene involved in the development of a rare endocrine tumour
Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours: there are only 3-8 cases...
Journal of Clinical Oncology.
CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
Aggressive prostate cancer, one of the leading causes of cancer deaths in men, is associated with...
The CNIO and Hospital 12 de Octubre find a potential new combination therapy against a rare disease of the bone marrow
Myelofibrosis is a severe and very rare haematological disease for which treatment has only been...
The New England Journal of Medicine (NEJM).
An international clinical trial extends the effectiveness of immunotherapy to more lung cancer patients
The strategy for triggering the patient’s own immune system to attack cancer, immunotherapy, is...
A new methodology predicts the risk of relapse in patients with acute myeloid leukemia
The acute myeloid leukemia (AML) is the most common haematological cancer in adults. With a 5-year...
First blood-based biomarker in response to the treatment of the most aggressive prostate cancer
In collaboration with British and Italian researchers
U.S. Department of Defense will finance a new therapeutic approach against the most aggressive type of prostate cancer
Coinciding with ‘Movember’, a month that raises awareness of men’s health issues
Política de privacidad